Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Licenses Stanford Biomarker Panel for Peripheral Artery Disease

NEW YORK (GenomeWeb News) — Vermillion has licensed a biomarker panel from Stanford University that could be used to assess the risk of peripheral artery disease, the company said today.
The agreement gives Vermillion exclusive rights to develop and commercialize a blood-based PAD test, which would use the multi-marker panel to stratify individual risk for developing the disease.
The company said PAD, which can result in complications such as gangrene, heart attack, stroke, and death, may affect as many as 12 million Americans.
The agreement builds on an existing collaboration between Vermillion (formerly called Ciphergen) and Stanford on PAD biomarker development. Last January, Ciphergen said it had signed an agreement with Quest to develop a blood-based test for the disease through a partnership with the university.
Vermillion, based in Fremont, Calif., said today that it also worked with Stanford to conduct a 540-patient, collaborative clinical evaluation study of the biomarker panel to classify individuals into high- and low-risk groups for PAD.
The company said the results of the study will be published in a peer-reviewed clinical journal “in the coming months.”
Financial terms of the biomarker licensing agreement were not released.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.